Cargando…

Combination of Irinotecan and a Platinum Agent for Poorly Differentiated Neuroendocrine Carcinomas

Extrapulmonary poorly differentiated neuroendocrine carcinoma (PDNEC) is a rare and highly aggressive neoplasm for which the optimal chemotherapy remains unclear. The objective of this study was to evaluate the outcomes of patients with PDNEC treated with cisplatin and irinotecan (IP) and perform a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramella Munhoz, Rodrigo, de Mendonça Rego, Juliana Florinda, de Celis Ferrari, Anezka Rubim, Ignez Braghiroli, Maria, Mendonça Bariani, Giovanni, Marcelo Hoff, Paulo, Perego Costa, Frederico, Eduardo Flesch Pfiffer, Túlio, Riechelmann, Rachel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications, Pavia, Italy 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3804814/ https://www.ncbi.nlm.nih.gov/pubmed/24179651 http://dx.doi.org/10.4081/rt.2013.e39

Ejemplares similares

Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer
por: de M Rêgo, Juliana Florinda, et al.
Publicado: (2017)

Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas
por: Braghiroli, Maria Ignez, et al.
Publicado: (2015)

A Prospective Cohort Study of Biomarkers in Squamous Cell Carcinoma of the Anal Canal (SCCAC) and their Influence on Treatment Outcomes
por: Moniz, Camila Motta Venchiarutti, et al.
Publicado: (2021)

Carcinoid syndrome: update on the pathophysiology and treatment
por: de Celis Ferrari, Anezka C. Rubin, et al.
Publicado: (2018)

Combination of Capecitabine and Oxaliplatin is an Effective Treatment Option for Advanced Neuroendocrine Tumors
por: Ferrarotto, Renata, et al.
Publicado: (2013)

TSC2 rare germline variants in non-tuberous sclerosis patients with neuroendocrine neoplasias
por: Asprino, Paula Fontes, et al.
Publicado: (2017)

Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma
por: Marta, Guilherme Nader, et al.
Publicado: (2021)

Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group
por: Riechelmann, Rachel P, et al.
Publicado: (2017)

Validation of questionnaire on the Spiritual Needs Assessment for Patients (SNAP) questionnaire in Brazilian Portuguese
por: de Araujo Toloi, Diego, et al.
Publicado: (2016)

Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden: Two case reports
por: Mota, Jose Mauricio, et al.
Publicado: (2018)

Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer
por: Liu, Ying, et al.
Publicado: (2015)

Is the blood of a surgeon performing HIPEC contaminated by irinotecan, its major metabolites and platinum compounds?
por: Saint-Lorant, Guillaume, et al.
Publicado: (2021)

Biomarkers of Response to Etoposide-Platinum Chemotherapy in Patients with Grade 3 Neuroendocrine Neoplasms
por: Lacombe, Caroline, et al.
Publicado: (2021)

Analysis of Artifacts on MRI from Electronic Identification Enablement in Silicone Gel Implants
por: Munhoz, Alexandre Mendonça
Publicado: (2022)

Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane
por: Satake, Hironaga, et al.
Publicado: (2018)

Exceptional response to lurbinectedin and irinotecan in BRCA-mutated platinum-resistant ovarian cancer patient: a case report
por: Cortesi, Laura, et al.
Publicado: (2022)

Next-generation Sequencing-based genomic profiling: Fostering innovation in cancer care?
por: Fernandes, Gustavo S., et al.
Publicado: (2017)

Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib
por: da Fonseca, Leonardo Gomes, et al.
Publicado: (2018)

Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma
por: Ando, Takayuki, et al.
Publicado: (2015)

Prognostic Factors of Second and Third Line Chemotherapy Using 5-FU with Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer
por: Park, Ji Soo, et al.
Publicado: (2011)

Multicenter Retrospective Analysis of Chemotherapy for Advanced Pancreatic Acinar Cell Carcinoma: Potential Efficacy of Platinum- and Irinotecan-Containing Regimens
por: Takahashi, Hideaki, et al.
Publicado: (2021)

Long-term disease-free survivor of metastatic large-cell neuroendocrine carcinoma of the lung treated with amrubicin and irinotecan
por: Ryuge, Shinichiro, et al.
Publicado: (2009)

A Simple and Low-cost Method of Sleeve to Insert Silicone Gel Breast Implants
por: Panczel, Georg, et al.
Publicado: (2019)

Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis
por: Xu, Fei, et al.
Publicado: (2018)

METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours
por: Glasberg, João, et al.
Publicado: (2022)

METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours
por: Glasberg, João, et al.
Publicado: (2022)

Irinotecan toxicity: genes or intestinal microflora?
por: Brandi, G, et al.
Publicado: (2009)

Is cachexia associated with chemotherapy toxicities in gastrointestinal cancer patients? A prospective study
por: da Rocha, Ilanna Marques Gomes, et al.
Publicado: (2019)

Effects of methimazole on the elimination of irinotecan
por: van der Bol, Jessica M., et al.
Publicado: (2010)

Carcinoid Heart Disease and Decreased Overall Survival among Patients with Neuroendocrine Tumors: A Retrospective Multicenter Latin American Cohort Study
por: Uema, Deise, et al.
Publicado: (2019)

A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients
por: Mabro, M, et al.
Publicado: (2006)

The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis
por: Guan, Yelan, et al.
Publicado: (2023)

Tailored-dose chemotherapy with gemcitabine and irinotecan in patients with platinum-refractory/resistant ovarian or primary peritoneal cancer: a phase II trial
por: Tate, Shinichi, et al.
Publicado: (2020)

Irinotecan-Induced Dysarthria
por: Dressel, Albertine J., et al.
Publicado: (2012)

Microbiota-Host-Irinotecan Axis: A New Insight Toward Irinotecan Chemotherapy
por: Yue, Bei, et al.
Publicado: (2021)

Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
por: Mahdy, Marwa S., et al.
Publicado: (2023)

A systematic review of therapeutic strategies in gastroenteropancreatic grade 3 neuroendocrine tumors
por: Donadio, Mauro D., et al.
Publicado: (2023)

Nanotechnology, nanosurfaces and silicone gel breast implants: current aspects
por: Mendonça Munhoz, Alexandre, et al.
Publicado: (2017)

Synergistic Effects of Simvastatin and Irinotecan against Colon Cancer Cells with or without Irinotecan Resistance
por: Jang, Hyun Joo, et al.
Publicado: (2016)

Recent advances in understanding antitumor immunity
por: Munhoz, Rodrigo Ramella, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7n2f9aeeci2jl52e9dchomu0fi